OncoTEX and researchers from the University of Texas and MD Anderson Cancer Center are developing a novel compound that delivers cancer drugs directly to cancer cells, avoiding healthy cells and limiting toxic side effects. The first compound in development is OxaliTex, a conjugation of texaphyrin and oxaliplatin, from the platinum drug class.
Texaphyrin carries oxaliplatin to the cancerous tumor cells. Inside the nucleus, OxaliTex goes through an oxidative reaction, activating the oxaliplatin as a cytotoxic agent. This process destroys the tumor cell from within, improving efficacy and overcoming drug resistance.
T-cell Engager Platform
Decoding Cancer Immunology
Our pride and reputation are in everything we deliver.
Visit our process page to see how our award winning animations get created.